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The disuhide bridges of human complement component C3b, derived from C3 by removal of the 77-residue C3a, have been determined. The 10 
bridges are Cy~‘~‘_Cys’~“, Cys@‘-Cysw, Cy~*~‘-Cys’~~‘, Cy~‘~‘~-Cys”‘~, Cy~“~~_Cys’~~‘, Cy~‘~~‘-Cys’~~~, Cy~‘~@‘_Cys“‘~~, Cy~‘@‘Zys”~, C~S”“- 
cys?, and Cy~‘~‘~_Cys’~~“. Including the 3 bridges in C3a (Cy~~‘~Cys~s, Cy~~‘*-Cys’~~, and Cys6”_Cys7”) previously determined by htgh- 
resolution X-ray crystallography [Hoppe-Seyler’s Z. Physiol. Chem. 361 (1980) 1389-13991 all disulfide bridges of C3 are localized. C3 and the 
strongly related C4 and C5 are members of the a,-macroglobulin superfamily. The predicted bridge patterns of C4 and CS are discussed and 
compared with that of a,-macroglobulin. 
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1. INTRODUCTION 
The third component of human complement, C3, 
consists of a 75-kDa B-chain disulfide bridged to a 115 
kDa a-chain [l]. C3 plays an important effector role in 
the immune response, and it is operative at a point 
where the classical and alternative pathways converge. 
It is activated by the physiological complex proteinases 
C4bC2a or C3bBb [2]. This activation results in the 
formation of fragments C3a and C3b. C3a consists of 
the N-terminal 77 residues of the cc-chain [1,2]. The 
large C3b fragment binds covalently to biological tar- 
gets, e.g. membrane constituents and to antibody 
through a transacylation reaction effected by an acti- 
vated internal /I-Cys-y-Glu thiol ester located in the 
a-chain [3-51. C3b can be cleaved by several proteinases 
in its a’-chain resulting in the major fragments C3c and 
C3d [6]. Different parts of the C3 structure can be recog- 
nized by specific receptors, which are important for the 
regulation of complement activity [7]. 
C3 and the related complement components C4 and 
C5 are members of the a,M superfamily [8]. The amino 
acid sequences of human C3 [9], C4 [lo], C5 [ll], and 
a,M [12] are known, but the complete disulfide bridge 
pattern is only known for a,M [12,13]. From the high 
resolution X-ray structure of C3a its three disulfide 
bridges have been determined [14], but only limited in- 
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Sephadex G-50 SF, Superose 12, Q and S Sepharose FF were from 
Pharmacia. 4 x 250 mm columns were packed with PolySUL- 
FOETHYL-A, 5 ,um from PolyLC Inc, and with Nucleosil 100-5 Cl8 
from Machery-Nagel. Standard chemicals were of analytical grade 
from Merck and Sigma. 
2.3. Separation of peptides by HPLC 
Abbreviations: C3(MA), C3 treated with methylamine and iodoacet- Pools containing peptides judged to be less than approx. 50 residues 
amide; a,M, a,-macroglobulin; HPLC, high-performance liquid in length were separated on polySULFOETHYL-A using a phos- 
chromatography; RP, reverse phase; SCX, strong cation exchange; phoric acid/NaCl/acetonitrile based SCX-HPLC system [17,18]. Se- 
TFA, trifluoroacetic acid; PTH, phenylthiohydantoin. lected pools were further separated by RP-HPLC on a Nucleosil Cl8 
formation on the location of the remaining bridges of 
C3 is available from partial reduction experiments 
[15,16]. 
Here we report the location of the 10 disulfide bridges 
in human C3b. The putative arrangement of the disul- 
fide bridges in the related proteins C4 and C5 is dis- 
cussed, and their bridge patterns are compared with 
that of human a?M. 
2. MATERIALS AND METHODS 
2.1. Proteins 
Human C3 was prepared from the 3-108 polyethylene glycol pre- 
cipitate obtained from fresh pooled plasma essentially according to 
ref. [l]. The final purification step consisted of chromatography on Q 
Sepharose FF (load 75 mg, column size 1 x 30 cm, 20 mM Na-phos- 
phate, pH 7.4, 50-500 mM gradient of NaCI). By sodium dodecyl 
sulfate gel electrophoresis only bands corresponding to the a- and 
B-chains of C3 were seen as confirmed by sequence analysis of elec- 
troblotted samples. C3 was treated with methylamine to cleave the 
internal thiol ester [4] and the SH group blocked by reaction with 
iodoacetamide. C3b(MA) was prepared from C3(MA) by incubation 
with 11100 (w/w) trypsin for 10 min at 37°C followed by chromatogra- 
phy on Q Sepharose FF as above. Tosyl-phenylalanine chlorometh- 
ylketone-treated bovine trypsin was from Cooper Biomedicals. Staph- 
ylococcus aureus V8 proteinase was from Miles. Porcine pepsin was 
from Worthington. 
2.2. Column materials and chemicals 
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Fig. 1. SCX-HPLC separations of CNBr/tryptic peptides from C3b(MA) (panel A) and CNBr/peptic peptides from C3(MA) (panels B and C). 
A 4 x 250 mm column packed with polySULFOETHYL-A was equilibrated with 5 mM phosphoric acid/l0 mM NaCU25% acetonitrile and eluted 
at 40°C with a gradient of NaCl (----) (100% B corresponds to 1 M NaCl in the solvent). The flow rate was 1 mhmin, and the separations were 
monitored by recording A,, (-) and by determining the amount of halfcystine in each fraction (vertical bars). The separation shown in panel A 
represents l/2 of the Superose 12 pool, whereas those shown in panels B and C represent l/6 of the Sephadex G50 SF pools. The pools/fractions 
further separated by RP-HPLC (l/4 to l/2 used) are marked by horizontal bars. 
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column eluted at a flow rate of 1 ml/min with a linear gradient formed 
from 0.1% TFA (A) and 90% acetonitrile containing 0.075% TFA (B) 
(l&60% B). The gradient was developed over 25 min, and the separa- 
tions at 50°C were monitored by recording the absorbance at 226 nm. 
Disulfide-bridged peptides in the effluents were located by determin- 
ing the content of Cya in performic acid oxidised samples or by 
RP-HPLC of reduced and carboxymidomethylated samples (2 mM 
dithiothreitol for 15 min at pH 9.0 followed by 5 mM iodoacetamide 
for 30 min). 
2.4. Amino acid analysis 
Peptides were hydrolyzed with 6 M HCl/l% thioglycolic acid for 20 
h at 110°C in evacuated sealed tubes or in the gas phase using an 
evacuated esiccator. Most samples were analyzed after treatment 
with 1 M performic acid for 30 min at room temperature. Free amino 
acids were separated by SCX-HPLC on a 4 x 125 mm Mitsubishi 
CKlOU column using a pH gradient ranging from 3.10 @la-citrate/ 
sulfate) to 10.10 (Na-borate) essentially as described [19]. 
2.5. Sequence analysis 
Edman degradations were done for 410 cycles in an Applied Bio- 
systems 477A sequenator equipped with an 120A on-line HPLC using 
polybrene-coated glass-filters and Normal-l cycles. Initial yields were 
100-500 pmol. 
2.6. Experimental details 
Digest 1: 58 mg C3b (MA) was degraded with CNBr in 70% formic 
acid and the digest separated on a 1 x 10 cm S Sepharose FF column 
eluted with a &I M gradient of NaCl in 10 mM ammonium acetate, 
6 M urea, pH 4.5. No significant fractionation occurred, and 4.5 ml 
portions of the material in the main irregular peak eluting at 0.43-0.78 
M NaCl was loaded onto a 160 ml Superose 12 column eluted with 
25% formic acid (10 runs, not shown). The material eluting at 0.32- 
0.50 bed ~01s. containing more than 90% of Cys, present was pooled, 
freeze-dried, dissolved in 0.1% TFA, made 0.1 M in ammonium bicar- 
bonate, and digested with 120 pg trypsin for 2 h at 37°C. Aliquots of 
the digest were separated by SCX-HPLC, and pools A-N (Fig. IA) 
were further purified by RP-HLC (not shown). 
Digest 2: 59 mg C3 (MA) was dissolved in 0.1 M formic acid and 
digested with 1 mg pepsin for 3 h at 37°C. After freeze-drying the 
material was treated with CNBr in 70% formic acid and the peptides 
separated on a 180 ml column of Sephadex G 50 SF eluted with 1 M 
formic acid (not shown). More than 95% of Cys, present was found 
in effluent at 0.25-0.80 bed ~01s. Aliquots of two pools containing 
relatively small peptides eluting at 0.52-0.67 bed vols (pool I), and 
0.68-0.80 bed ~01s. (pool 2) were separately subjected to SCX-HPLC. 
Individual fractions from these separations (marked in Fig. 1B and C) 
were further separated by RP-HPLC (not shown). 
3. RESULTS 
Since the sequence of C3 is known [9], the main strat- 
egy for locating its disulfide bridges consisted of com- 
positional analysis and partial sequence analysis of pep- 
tides having intact bridges. In a few cases the mates of 
bridged peptides were characterized after reduction and 
alkylation. 
To avoid thioldisulfide exchange reactions resulting 
from thiol ester cleavage C3 was treated with methylam- 
ine, forming C3 (MA), and the SH-group appearing [4] 
blocked with iodoacetamide. Since the bridges of the 
C3a portion were already known [14], C3b (MA) was 
used as starting material for the first digest. Degrada- 
tion with CNBr followed by digestion with trypsin 
would be advantageous, ince it could be expected that 
most bridged peptides would contain only 1 bridge. The 
CNBr fragments were subjected to cation-exchange 
chromatography followed by gel chromatography 
under denaturing conditions to possibly obtain larger 
sets of bridged fragments which could be further di- 
gested. However, no significant separation of such frag- 
ments was obtained. The main pool obtained was then 
digested with trypsin and the peptides separated by 
SCX-HPLC at pH 3.0 (Fig. 1A) followed by RP-HPLC. 
Due to the complexity of the digest only 6 bridges 
could be located, and therefore a second digest was 
investigated. In this, C3 (MA) was degraded with pepsin 
followed by digestion with CNBr. The bridges not 
found in the first digest were planned to be present in 
relatively small peptides in the second digest. Therefore, 
the peptides were fractionated by gel chromatography 
on Sephadex G50 SF, and two pools containing small 
peptides were further separated by SCX-HPLC (Figs. 
1B and C) and RP-HPLC. The peptide pools of the 
digest were examined until the remaining 4 disulfide 
bridges were found. 
As summarized in Table I the minimal evidence for 
locating the 10 disulfide bridges in C3b was provided by 
10 unique peptides or mates hereof. Most bridged pep- 
tides, in particular those derived from peptic digestion, 
were recovered as several cleavage variants which were 
also characterized (not shown). 
The evidence for locating the bridges in peptides 2, 5, 
6, 7 and 10 was obtained from analysis of the intact 
peptides. The disulfide bridges in peptides 2, 5 and 6 
connected two mates, while peptides 7 and 10 each con- 
tained an internal bridge. Peptides 1, 4 and 9 were 
slightly impure, and the evidence for locating their 
bridges was obtained after separating their reduced and 
carboxamidomethylated mates by RP-HPLC. Peptides 
3 and 8 were obtained by subdigesting a peptide set, 
which by compositional analysis was shown to contain 
the stretch C149’ AEENCFIQK connected to 2 other 
peptides, with S. aureus V8 proteinase followed by sep- 
aration of the 2 peptide sets by RP-HPLC. Both pep- 
tides contained a bridge connecting two mates. 
In the Sephadex G 50 SF gel chromatography used 
in digest 2 a large cluster of peptic peptides eluting at 
0.25-0.51 bed ~01s. and containing the 3 bridges in the 
C3a portion was obtained (not shown). As the location 
of these bridges was already determined from X-ray 
crystallography [14] that material was not further inves- 
tigated. 
4. DISCUSSION 
This work provides unequivocal evidence for the lo- 
cation of the 10 disulfide bridges in C3b. It identifies the 
single bridge in C3d and the bridges inferred from par- 
tial reduction experiments to connect the 01- and /?- 
chains of C3, and the N- and C-terminal pieces of the 
cleaved a-chain of C3c [15,16]. The recent incomplete 
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Table I 
Summary of the evidence for the location of the 10 disulfide bridges in human C3b”. 
Peptide I: Cy~~~‘-Cys’~~ (Fig. lC, fraction 32, 54% B, 34% B and 38% B, 1.1 nmol)” 
Mate 1: C,,,,,,B,,,,,,S,B(*,rG,~,l,rVt~~))rL,~,~)rK~5,~;.d 
Mate 2: C B S Z P G,Z,~,.A, 2,1jrV~ ,,,,I,,o,,F,,(,,,Kzatz,E~ cl8,1,, 21(2). 08(1,, 10,1,. 10(l), 
Sequence, mate 1: V’“DVK(DSCVGSL) 
Sequence, mate 2: S’s*DKK(GICVADPFE) 
Peptrde 2: Cysbo5 -CysMo (Fig. IA pool B. 39% B, 3.5 nmol)” 
Intact peptide: C B 20,2)? 3 3 T ,3p 3 6(4,r S 4 3 Z m 5 7 P (6,. 2 8 01, 65,7,1 09,1~~ ,0,1,> 2om. G,,,,,,A V I L 
Y F, s&, o,uA O,II CS 09,1P
Sequence: A60’DIGC(TPGSGKDYAGVFSDAGLTFTSSSGQQTAQR)g 
A6=‘ELQC(PQPAAykg 
Peptide 3: Cy~*~‘-Cys’@ (Fig. 1A pool K, 38% B, 36% B, 1.8 nmol)’ 
Intact peptide: C _ B T S 21tv IO,,,,2”(2). 09,1,, Z 9(2,.P,,,,,.A27(3,,L10(3).FI ocl,.H, x,r,.Ki , ,,7 
Sequence: L844LHNP(AFCSLATTKpg 
X’49’AEEh 
Peptide 4: Cy~‘~‘~~Cys”~~ (Fig. 1B fraction 24. 48% B, 46% B and 44% B. 0.6 nmoBb 
Mate l:C,,,,,B, O,l,S1 5,r,.Z, zo,,G,4uj,A2 I~,.VI 9&i s(~,.LI I o,.K,s,,,‘d 
Mate 2: C,,,,,,B,,,?,,T S Z P 101,1), 29(3)> 50,5,, I3,lP Gzs,z,,Az5(21.V~2,1).I?9,31,L?3,21,K~3,~;.d 
Sequence, mate 1: I’07’AIDS(QVLCGAVKW) 
Sequence, mate 2: I”‘5SLQE(AKDICEEQVNSLPGSITKAG) 
Peptide 5: Cy~‘~~“-Cys“‘~’ (Fig. 1A pool I, 36% B, 5.0 nmol)” 
Intact pepttde: C, , ,2$%4 ,4j,T1 7 ,z,& 7,1,Z2 v ,3,Aj 9c21.Vo9,1J3 o 1 ,.Y~7t3J1 OW.K~ 1 ,W 
R c.e IO11) 
Sequence: A’330KDQL(TCNKFDLK)E,g 
V’457YAYY(NLEESCTRFg 
Peptide 6: Cy~‘~~‘-Cys”~~ (Fig. 1A pool H. 38% B. 0.5 nmollb 
Intact pepttde: C, 5 ojr B T S Z 19,2,3 lo,,,. 17r2b 20(2,. A, ,,,,,V, ,,,,.I, ,,z,,Lz, ,z,>F,,,,,,H, ,wK, I ,,,A I ,I? 
Sequence: I’363LEIX(TR)Ep.h 
V’429SHSE(DDCLAFK)E,p 
Peptide 7: Cy~‘~~~~Cys’~” (Fig. IA pool D, 36% B, 2.2 nmol)b 
Intact peptide: C, o d$ o ,,,,Z, o ,,,& d% o ,?P.e 
Sequence: L’483XRDELCRh.‘J 
Peptide 8: Cy~‘~‘~%ys’~~~ (Fig. IA pool K. 38% B, 16% B. 1.8 nmoBb 
Intact peptide: C? I d% 2,1JA I ,J, oc~Pl o,I&~dl 0~;~ 
Sequence: N’495CFIQKB,k 
X1568Rg.h 
Peptide 9: Cy~‘~‘~~Cys’~‘~ (Fig. 1C fraction 23, 40% B, 28% B and 34% B, 6.7 nmol)b 
Mate 1: C B I II ,I). 2 I tw Z * 9 (3P P, , ,,,.G, oc~,A, o,~,3V~ o ~,.LI I ,,&I I ,I&I ollFd 
Mate 2: C,,,,,.B, o,lr,P, o,l,.G, 2tI,,V101~PI O,l;d 
Sequence, mate 1: E’508ERLD(KACEPGVD)Eg 
Sequence, mate 2: V’635VFGX(PN)c.B.h 
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Peptide 10: Cys ‘6’5-Cys’624 (Fig. 1C fraction 15, 40% B, 7.5 nmol)b 
Intact peptide: C B Z P 18,ZP 40(4P SS,lO)7 I*(,), G, z&, o~,,,V~ I ,,,J+ oc~Pl.~cl~&~cl,E’ 
Sequence: V’@‘6EHWP (EEDECQDEENQKQCQDLGAYJ 
a The numbering of proC3 [9] is used. 
b The data in brackets show in succession the SCX-HPLC fraction, the percentage of solvent B required in RP-HPLC to elute the peptide with 
intact bridge, and the mates 1 and 2 after reduction and carboxamidomethylation r after subdigestion; the actual yield of intact peptide is listed. 
’ The numbers and residues in brackets show the expected numbers of residues and their sequences. 
d Cys was determined as S-carboxymethyl-Cys. 
’ Cys was determined as Cya. 
’ Bis-PTH-Cys, eluting close to PTH-Tyr was seen in cycle 5. 
8 The appearance of 2 PTH-derivatives per cycle was consistent with the partial sequences hown. 
h X indicates a Cys-residue. No PTH-derivative was seen in this cycle, consistent with the disulfide pairing. 
’ A small amount of his-PTH-Cys, was seen in cycle 7. 
1 Since only 1 sequence was seen the bridge is internal in the peptide. 
k Bis-PTH-Cys, was seen in cycle 2. 
description of the bridges in C3 [23] is consistent with 
the results described here. Together with previous 
cDNA analysis [9], localization of an internal thiol ester 
[4], determination of 3 bridges in C3a [14], structure 
determination of high-mannose-type carbohydrate 
groups [20,21] attached to Asn63 and Asn917 [22] the 
primary structure determination of C3 is completed. 
The disulfide bridges of C3 are shown schematically 
in Fig. 2. For a protein the size of C3 their number is 
strikingly low, and moreover, two segments, the C3a 
portion and the C-terminal approx. 300 residues of the 
a-chain contain several clustered bridges, while the /3- 
chain only contains 1 intrachain bridge. 
The complement proteins C4 and C5 are homologous 
with C3 [9-l l] and have many halfcystine residues in 
common with C3. Hence, their bridge patterns are likely 
to be similar to that of C3 as indicated in Fig. 2. How- 
ever, they differ subtly, since C4, relative to C3, is likely 
to have a unique bridge in the N-terminal part and also 
has an unpaired Cys residue at position 1103, and since 
C5 has an unpaired Cys residue in the C5a part, and 
likely a bridge in the stretch around residue 850 (Fig. 
2). 
Curiously, while C3, C4, and C5 are homologous 
with the a,M subunit [8], and while all these proteins 
probably contain many domains of similar gross con- 
formation, the bridge pattern of the a,M subunit is not 
similar to that of the complement proteins (Fig. 2), 
except for the presence of a short bridge just before the 
activation cleavage regions (the a,M bait region), a 
bridge spanning several hundred residues and a bridge 
spanning appr. 130 residues in the C-terminal part. 
However, the C-terminal approx. 150-residue stretches 
of C3, C4, and C5, which represent extensions relative 
to CQM, are unique and contain a conserved and intri- 
cately bridged domain. 
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Fig. 2. Schematic representation of the structure of C3 showing the location of the disulfide bridges determined here and before (C3a portion [14]). 
The putative disulfide bridge patterns of C4 and CS are shown as stippled lines. The bridges in a,M [12,13] are shown. The 2 halfcystine residues 
at position 255 and 408 in a,M form interchain bridges in the a,M half-molecule [13]. The a-, a’-, j?-, (C3, C4, C5) and y-chains (C4) are labeled 
and delimited by arrows. The approx. 77-residue C3a, C4a, and C5a parts, and the approx. 400-residue C3d and C4d parts are labeled (a) and 
(d), respectively, and delimited by arrows. C3c and C4c (not shown) are multiple chain structures formed from C3b and C4b by excision of the 
C3d and C4d parts [6]. The multiple cleavage sites in the a,M bait region [12] are indicated by 2 arrows. The thiol ester site in C3, C4, and a,M 
is labeled with an asterisk. The location of carbohydrate groups in C3 [22] and a,M [12] is shown by filled diamonds. Potential carbohydrate 
attachment sites in C4 [lo] and C5 [1 I] are shown by open diamonds. 
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